Interní Med. 2006; 8(10): 423-426

Sjögren‘s syndrome

MUDr. Hana Ciferská1, doc. MUDr. Pavel Horák CSc1, MUDr. Zuzana Heřmanová2, MUDr. Marta Ordeltová2, doc. MUDr. Josef Zadražil CSc1
1 III. interní klinika FN a LF UP Olomouc
2 Oddělení klinické imunologie, FN a UP Olomouc

Sjögren‘s syndrome (SS) is chronic, autoimmune and inflammatory disease with predominant affection of exocrine glands, but also extragrandular manifestations are common occurrence. There are two forms of SS primary and secondary. Secondary SS is connected to presence of other autoimmune disease (rheumatoid arthritis, systemic lupus erythematosus etc.) For this disease is typical production of specific auto antibodies anti-SS-A (anti-Ro) and anti-SS-B (anti-La) and lymphocytary infiltration of exocrine glands. The treatment of SS is mainly symptomatic in the patients without organ manifestation. If the organ manifestation is present, the immunosuppressive therapy is prescribed. The patients with SS have higher risk of occurrence of non-Hodgkin lymphomas.

Keywords: Key words: Sjögren‘s syndrome, anti-SS-A (Ro), anti-SS-B (La), exocrine secretion, autoimmune disease.

Published: February 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ciferská H, Horák P, Heřmanová Z, Ordeltová M, Zadražil J. Sjögren‘s syndrome. Interní Med. 2006;8(10):423-426.
Download citation

References

  1. Drosos AA, Skopuli FN, Costopoulos JS, et al. Cyclosporin A (CyA) in primary Sjögren´s syndrome: double blind study. Ann. Rheum. Dis. 1986; 45: 732-735. Go to original source... Go to PubMed...
  2. Haga HJ, Hulten B, Bolstad AL, et. al. Reliability and sensitivity of the diagnostic tests for primary Sjögren´s syndrome. J. Rheum. 1999; 26: 604-608.
  3. Chudwin DS, Daniels TE, Warad W, et al. Spectrum of Sjögren´s syndrome in children. J. Pediatry 1981. 98: 213-217. Go to original source... Go to PubMed...
  4. Ichikawa Y, Shimizu H, Takahashi K, et al. Lymphocyte subsets of the peripheral blood in Sjögren´s syndrome and rheumatoid arthritis. Clin. Exp. Rehum. 1989; 7: 55-61.
  5. Janin A, Morel P, Quiquandon I, et al. Non-Hodgkin´s lymphoma and Sjögren´s syndrome: An immunopathological study of 113 patients. Clin. Exp. Rheum. 1992; 10: 565-570.
  6. Jean S, Quelvenec E, Alizadech M, et al. DRB1*15 and DRB1*03 extended haplotype interaction in primary Sjögren´s syndrome genetic susceptibility. Clin. Exp. Rheum. 1998; 16: 725-728.
  7. Kong L, Ogawa N. Fas and Fas ligand expresion in salivary glands of patients with primary Sjögren´s syndrome. Arthritis. Rheum. 1997; 40: 87-97. Go to original source... Go to PubMed...
  8. Leber TH. Uber die entstenhung der netzhautablosung. Klin. Monatsbl. Augenheilkd. 1882; 20: 165.
  9. Mikulicz J. In discussion at Verein fur wissenschaftliche Heilkunde zu Konigsberg. Berl. Klin. Wochenschr. 1888; 25: 759.
  10. Pavelka K. a kolektiv autorů: Farmakoterapie revmatických onemocnění. Grada 2005: 291-293.
  11. Pavelka K, Rovenský J. et al.: Klinická revmatologie Galén 2003; 303-309.
  12. Pillemer SR. Matteson EL, Jacobson LT. et al. Incidence of physician diagnose primary Sjögren´s syndrome in residents of Olmsted Country, Minnesota. Myao Clin. Proc. 2001; 76: 593-596. Go to original source... Go to PubMed...
  13. Sjögren H. Zur Kenntnis der keratoconjuctivitis sicca. Act. Ophtalmol. 1933; 11: 1-151.
  14. Strckland RW,Tesar JT, Berne BH, et al. The frequency of sicca syndrome in erderly female population. J. Rheumatol. 1987; 14: 766-771. Go to PubMed...
  15. Skopouli FN. Dafni U, Ioannidis JP, et al. Clinical evolution and morbidity and mortality in primary Sjögren´s syndrome. Arthritis Rheum. 2000; 29: 296-304. Go to original source... Go to PubMed...
  16. Talal N. Recent developments in the immunology of Sjögren´s syndrome. Scand. J. Rheum. 1986; 61: 76-82.
  17. Tengner P, Halse AK, Haga HJ, et al. Detection of anti-Ro/SSA and antiLA/SSB. autoantibody-producing cells in salivary glans of patients with Sjögren´s syndrome. Arthtitis Rheum. 1998; 41: 2238-2248. Go to original source...
  18. Vitali C, Bombardiere S, Jonsson R, et al. Classification criteria for Sjögren´s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. 2002; 61: 554-558. Go to original source... Go to PubMed...
  19. Whittingham S, McNeilige J, Mackay IR. Primary Sjögren´s syndrome after infectious mononucleosis. Ann. Intern. Med. 1985; 102: 490-493. Go to original source... Go to PubMed...
  20. Zulman J, Jaffe R, Tatal N. Evidence that the malignit lamyphoma of Sjögren´s syndrome is a monoclonal B-cell neoplasm. New Eng. Med. 1978; 299: 1215-1220. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.